Preparing for semaglutide treatment extends beyond technical mixing to include comprehensive clinical readiness
As a GLP-1 (glucagon-like peptide-1) receptor agonist, Ozempic stands out from other medications in its class due to several unique characteristics that directly benefit our patients
Real evidence: A 12-week study: submaximal semaglutide improved metabolic markers but showed no change in the inflammatory markers IL-6, TNF-, or PAI-1 Semaglutide dose-response studies: effects require 0.2 mg/day, and even those effects are diminished when adjusted for weight change Meta-analyses showing anti-inflammatory effects correlate with improvements in insulin resistance and weight loss, not with microdosing voodoo magic
Importantly, these studies compare outcomes with those of patients receiving other diabetes medications
In addition to increasing insulin release, the GLP-1 hormone also: By mimicking the hormones action, GLP-1 drugs can help lower blood sugar and help you lose weight by making you feel more satisfied after eating
.png)
